Allergan Tazoral "not approvable"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Allergan will continue seeking a psoriasis indication for its oral tazarotene product Tazoral, the firm says following FDA's Sept. 24 "not approvable" letter. Among the "non-approvability issues" are the needs for a non-inferiority trial in severe psoriasis, an "acceptable" risk management plan and manufacturing deficiencies. Allergan "will work with the FDA to clarify" the request for a non-inferiority trial. The firm says it is "in the process of developing an appropriate risk mangement plan." The manufacturing issue "is either resolved or will be resolved shortly to the FDA's satisfaction," Allergan says. FDA's Dermatologic & Ophthalmic Drugs/Drug Safety & Risk Management advisory committees said that the Tazoral risk management plan was inadequate during a July 12 joint meeting...
You may also be interested in...
Seasonale Lo filing by June 30
Allergan plans to conduct an FDA-requested clinical study of its oral tazarotene formulation Tazoral, as well as provide additional pharmacology and toxicology data, the firm says June 1 after receiving FDA's written response to a dispute resolution request for a September 2004 "not approvable" letter. The agency "outlined multiple potential options for improving oral tazarotene's risk-benefit profile," Allergan stated. "Based on…F DA's recommendations, Allergan plans to submit a development plan…a nd will provide details once an agreement has been reached." A July 2004 advisory committee deemed the company's risk management plan for the retinoid to be inadequate (1Pharmaceutical Approvals Monthly October 2004, In Brief)...
Allergan Tazoral regulatory update
Allergan plans to conduct an FDA-requested clinical study of its oral tazarotene formulation Tazoral, as well as provide additional pharmacology and toxicology data, the firm says June 1 after receiving FDA's written response to a dispute resolution request for a September 2004 "not approvable" letter. The agency "outlined multiple potential options for improving oral tazarotene's risk-benefit profile," Allergan stated. "Based on…F DA's recommendations, Allergan plans to submit a development plan…a nd will provide details once an agreement has been reached." A July 2004 advisory committee deemed the company's risk management plan for the retinoid to be inadequate (1Pharmaceutical Approvals Monthly October 2004, In Brief)...
Can Organovo Leverage Its Solid Phase II Data In MASH?
Cash-limited Organovo has an FXR agonist showing competitive efficacy and tolerability in MASH, but may need a partner to move forward in that disease as it may be prioritizing its IBD program.